Article
Overcoming KRAS-Mutant Lung Cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Apr 2022
Luo Jia, Ostrem Jonathan, Pellini Bruna, Imbody Denis, Stern Yaakov, Solanki Hitendra S, Haura Eric B, Villaruz Liza C
Abstract excerpt
More than 50 years after the discovery of RAS family proteins, which harbor the most common activating mutations in cancer, the U.S. Food and Drug Administration approved the first direct allele-specific inhibitor of mutant KRAS in lung cancer. We highlight the history of discovering RAS and decades of studies targeting KRAS-driven lung cancer. A landmark article by Shokat and colleagues in 2013 elucidated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.